close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc
Search

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.44 -11.66

Osta

Hinna uuendus 26. veebr 2026, 14:43 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.47

Max

1.6800000000000002

Põhinäitajad

By Trading Economics

Sissetulek

1.8M

-32M

Müük

-166K

1.7M

Kasumimarginaal

-1,852.384

Töötajad

181

EBITDA

7.9M

-29M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+193.21% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

3. märts 2026

Turustatistika

By TradingEconomics

Turukapital

48M

174M

Eelmine avamishind

13.1

Eelmine sulgemishind

1.44

Uudiste sentiment

By Acuity

50%

50%

167 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. veebr 2026, 23:25 UTC

Kuumad aktsiad

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

DJ

Loe

25. veebr 2026, 23:15 UTC

Tulu

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

DJ

Loe

25. veebr 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

DJ

Loe

25. veebr 2026, 23:47 UTC

Tulu

Ferrovial 4Q Net EUR197M >FER.MC

DJ

Loe

25. veebr 2026, 23:45 UTC

Tulu

Ferrovial 4Q Rev EUR2.72B >FER.MC

DJ

Loe

25. veebr 2026, 23:42 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

DJ

Loe

25. veebr 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Company's Business Operations Remain Normal >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

DJ

Loe

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY EPS CNY47.67 >TCOM

DJ

Loe

25. veebr 2026, 23:06 UTC

Tulu

Correction to Nvidia Fourth Quarter Results Article -- WSJ

DJ

Loe

25. veebr 2026, 23:01 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

DJ

Loe

25. veebr 2026, 23:00 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

DJ

Loe

25. veebr 2026, 23:00 UTC

Market Talk
Tulu

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

DJ

Loe

25. veebr 2026, 22:56 UTC

Market Talk
Tulu

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

DJ

Loe

25. veebr 2026, 22:43 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

DJ

Loe

25. veebr 2026, 22:40 UTC

Market Talk
Tulu

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

DJ

Loe

25. veebr 2026, 22:40 UTC

Tulu

Karoon Energy Says Search for New CFO Well Advanced

DJ

Loe

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says CFO Ray Church to Leave Company

DJ

Loe

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

DJ

Loe

25. veebr 2026, 22:38 UTC

Tulu

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

193.21% tõus

12 kuu keskmine prognoos

Keskmine 4.75 USD  193.21%

Kõrge 7 USD

Madal 2.5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Põhineb 2 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Very Strong Bullish Evidence

All events are bullish.

Pikk perspektiiv

No Evidence

There are no events.

Sentiment

By Acuity

167 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,014.52

↓-3.15%

JNJ

Johnson and Johnson

243.43

↓-0.55%

ABBV

AbbVie Inc

224.55

↓-3.14%

NVS

Novartis AG

165.62

↓-1.16%

MRK

Merck & Co Inc.

120.01

↓-3.14%
help-icon Live chat